All In Biotech

Drug Trial Radar · NCT01032135

Adaptive Treatment for Alcohol and Cocaine Dependence

Last checked: Nov 20, 2026Latest source record: Sep 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Oct 2008

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 15, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Primary objective #1: Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use over weeks 1-24. * Hypothesis 1: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce higher rates of treatment engagement than an intervention focused on engagement in IOP only (e.g., MI-IOP). * Hypothesis 2: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce better cocaine/alcohol use outcomes than an intervention focused on engagement in IOP only (MI-IOP). * Secondary analysis 1: Among the Non-engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option. * Secondary analysis 2: Among the Engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option. 2. Primary objective #2: Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use outcomes over weeks 1-24. * Hypothesis 1: The predicted main effect on retention favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group. * Hypothesis 2: The predicted main effect on cocaine/alcohol use outcomes favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.

Conditions

  • Substance Use Disorders

Interventions

  • Motivational InterviewingBehavioral

    2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.

  • Telephone counselingBehavioral

    one telephone counseling session per week for 10 weeks.

  • Cognitive Behavioral Therapy (CBT) CounselingBehavioral

    One CBT session per week, for 10 weeks.

  • medication managementDrug

    Prescription for naltrexone

  • Intensive OutPatient TherapyBehavioral

    Return to IOP, group therapy 3 times weekly for about three hours a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment EngagementTime frame: weeks 3 - 12
  2. Treatment Engagement for Participants Engaged at 2 Weeks, But Disengage Before 8 WeeksTime frame: weeks 9 - 12
  3. Treatment Engagement of Those Non-engaged at 2 Weeks and at 8 WeeksTime frame: weeks 9 - 12
  4. Any Drinking Days in Previous MonthTime frame: Month 2 (weeks 5 - 8 post baseline)
  5. Any Drinking Days in Previous MonthTime frame: Month 3 (weeks 9 - 12 post baseline)
  6. Any DrinkingTime frame: Month 4 (weeks 13 - 15 post baseline)
  7. Any DrinkingTime frame: Month 5 (weeks 16 - 20 post baseline)
  8. Any DrinkingTime frame: Month 6 (weeks 21 - 24 post baseline)
  9. Percent Days DrinkingTime frame: Month 2 (weeks 5 - 8 post baseline)
  10. Percent Days DrinkingTime frame: Month 3 (weeks 9 - 12 post baseline)
  11. Percent Days DrinkingTime frame: Month 4 (weeks 13 - 16 post baseline)
  12. Percent Days DrinkingTime frame: Month 5 (weeks 17 - 20 post baseline)
  13. Percent Days DrinkingTime frame: Month 6 (weeks 21 - 24)
  14. Any Heavy Drinking DaysTime frame: Month 2 (weeks 5 - 8 post baseline)
  15. Any Heavy Drinking DaysTime frame: Month 3 (weeks 9 - 12 post baseline)
  16. Any Heavy Drinking DaysTime frame: Month 4 (weeks 13 - 16 post baseline)
  17. Any Heavy Drinking DaysTime frame: Month 5 (weeks 17 to 20 post baseline)
  18. Any Heavy Drinking DaysTime frame: Month 6 (weeks 21 - 24 post baseline)
  19. Percent Days Heavy DrinkingTime frame: Month 2 (weeks 5 - 8 post baseline)
  20. Percent Days Heavy DrinkingTime frame: Month 3 (weeks 9 - 12 post baseline)
  21. Percent Days Heavy DrinkingTime frame: Month 4 (weeks 13 - 16 post baseline)
  22. Percent Days Heavy DrinkingTime frame: Month 5 ( weeks 17 - 20 post baseline)
  23. Percent Days Heavy DrinkingTime frame: Month 6 (weeks 21 - 24 post baseline)
  24. Any Cocaine UseTime frame: Month 3 (weeks 9 - 12 post baseline)
  25. Any Cocaine UseTime frame: Month 4 (weeks 13 - 16 post baseline)
  26. Any Cocaine UseTime frame: Month 5 (weeks 17 - 20 post baseline)
  27. Any Cocaine UseTime frame: Month 6 (weeks 21 - 24 post baseline)
  28. Percent Days Cocaine UseTime frame: Month 3 (weeks 9 - 12 post baseline)
  29. Percent Days Cocaine UseTime frame: Month 5 (weeks 17 - 20 post baseline)
  30. Percent Days Cocaine UseTime frame: Month 6 (weeks 21 - 24 post baseline)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Presbyterian Medical Center

    Philadelphia, Pennsylvania

  • VAMC

    Philadelphia, Pennsylvania

  • NorthEast Treatment Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.